SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: TREND1, conix, Phaeton, $Pistol Pete$
Search This Board:
Last Post: 9/28/2016 3:18:45 PM - Followers: 352 - Board type: Free - Posts Today: 0


About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at:


Board of Directors

Alfred E. Mann

Alfred E. Mann has been one of our directors since April 1999, our Chairman of the Board since December 2001 and our Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio


Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge  A good forum for discussion on Mankind

MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.;;




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MNKD News: Current Report Filing (8-k) 09/22/2016 08:02:07 AM
MNKD News: MannKind Corporation to Present at the Rodman & Renshaw 18th Annual Global Investment Conference 09/02/2016 05:00:00 PM
MNKD News: Statement of Changes in Beneficial Ownership (4) 08/31/2016 05:38:18 PM
MNKD News: Statement of Changes in Beneficial Ownership (4) 08/31/2016 05:37:18 PM
MNKD News: Securities Registration: Employee Benefit Plan (s-8) 08/29/2016 04:31:55 PM
#19634  Sticky Note $MNKD MannKind Is 'Making Progress' On Its Alternative $Pistol Pete$ 08/30/16 04:46:19 PM
#19516  Sticky Note Nice blog article on MannKind. Phaeton 08/20/16 02:25:50 PM
#19781   najak from SA TREND1 09/28/16 03:18:45 PM
#19780   No thanks. I like my money Jumpinjackas 09/28/16 11:06:14 AM
#19779   Go for it . TREND1 09/28/16 11:03:23 AM
#19778   Huge. It will be huge. This delisting is Jumpinjackas 09/28/16 11:00:09 AM
#19777   MNKD WEEKLY TREND1 09/28/16 10:58:23 AM
#19776   MNKD will be at 10 long before scripts TREND1 09/28/16 10:56:01 AM
#19775   We just broke resistance MNKD dmcc2087 09/28/16 10:55:55 AM
#19774   Morning scan shows MNKD still on buy. TREND1 09/28/16 10:50:20 AM
#19773   scripts = 296 /week TREND1 09/28/16 10:46:37 AM
#19772   That's easy. Jumpinjackas 09/28/16 10:43:35 AM
#19771   Only 96.3 % more scripts per week to TREND1 09/28/16 10:41:09 AM
#19770   You will get a parabolic move once scripts Hypi 09/28/16 10:12:33 AM
#19769   At least 10. Jumpinjackas 09/28/16 09:10:13 AM
#19768   Like I said before revenue will continue to BUFCARP 09/27/16 10:40:32 PM
#19767   I hope we follow through tomorrow dmcc2087 09/27/16 05:24:23 PM
#19766   MannKind: New Prescription Sales Create Double-Digit Gains biginvestors 09/27/16 03:45:20 PM
#19765   Look like my system has a buy at TREND1 09/27/16 03:40:59 PM
#19764   Nice move up today MNKD dmcc2087 09/27/16 02:35:01 PM
#19763   Look like the bottom Brentpdc 09/27/16 01:55:16 PM
#19762   Buy low sell high MNKD dmcc2087 09/27/16 01:54:40 PM
#19761   The opportunity cost of staying invested in MNKD conix 09/27/16 01:29:45 PM
#19760   projected scripts to the end of 2016 TREND1 09/27/16 01:05:19 PM
#19759   scripts history TREND1 09/27/16 12:58:19 PM
#19758   MNKD is going to 6 soon. TREND1 09/27/16 12:54:18 PM
#19757   It's starting MNKD dmcc2087 09/27/16 11:25:50 AM
#19756   New all time low today TREND1 09/27/16 10:02:10 AM
#19755   Thinking all this selling could be Matt and Hypi 09/26/16 05:28:32 PM
#19754   Deflecting.. mmh ? This conversation is over. mc67 09/26/16 11:41:35 AM
#19753   need cash TREND1 09/26/16 11:38:51 AM
#19752   Need a lot of things, but having FDA Hypi 09/26/16 11:33:39 AM
#19751   9/16/16 This past week, Afrezza scripts came in TREND1 09/26/16 11:31:49 AM
#19750   New all time low Today. TREND1 09/26/16 11:27:48 AM
#19749   Will be interesting to see where investigations of kugel 09/26/16 09:48:13 AM
#19748   This will move back up revenue will grow BUFCARP 09/26/16 09:42:37 AM
#19747   I prefer drugs that serve a real purpose Hugodrax 09/26/16 08:00:34 AM
#19746   Sanofi were the ones who drew the shortest mc67 09/26/16 03:19:40 AM
#19745   You have to conserve the source of the Phaeton 09/25/16 11:22:04 PM
#19744   Doesn't matter. MannKind is going to zero. Hugodrax 09/25/16 10:58:02 PM
#19743   FRAUD Letter or comment from a Dr. What Hypi 09/25/16 10:07:14 PM
#19742   Afrezza gains market exposure... mc67 09/25/16 07:53:07 PM
#19740   Price and scripts is what investors should follow. IMHO. TREND1 09/25/16 12:49:16 PM
#19739   How many times a day do you test TREND1 09/25/16 10:04:27 AM
#19738   Amazing the misinformation out there.. SMH mc67 09/25/16 08:40:40 AM
#19737   Reviews for Afrezza "Please don't spread bad mc67 09/25/16 08:34:19 AM
#19736   Afrezza is a dud and the company is Hugodrax 09/24/16 05:31:32 PM
#19735   Hi Stump: Nope, and I don't have an Denise Chanterelle 09/24/16 01:03:39 PM
#19734   FROM TREND1 09/24/16 11:49:06 AM
#19733   is the end here! looking very bleak for mnkd. harry crumb 09/24/16 02:00:07 AM
#19732   * * $MNKD Video Chart 09-23-16 * * ClayTrader 09/23/16 04:57:19 PM
#19731   damn WHAT A DAY!! kugel 09/23/16 04:21:12 PM